精彩内容日前,齐鲁制药申报的4类仿制药盐酸决奈达隆片获批生产并视同过评,成为公司今年以来获批的第15个品种。盐酸决奈达隆片是一种抗心律失常药物,近年来在中国三大终端六大市场(统计范围详见本文末)的销售额均以两位数及以上的增速持续增长。来源:米内网一键检索盐酸决奈达隆片是赛诺菲开发的一种抗心律失常药物,适用于有阵发性或持续性心房颤动病史的窦性心律患者,减少因心房颤动(AF)住院的风险。米内网数据显示...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.